AbbVie Wins First Round in Humira Antitrust Lawsuit
The purpose of the secondary patent filings was to assemble a thicket of patents, 132 in all, to prohibit competition from biosimilar companies.
Pharmaceuticals
-
Read more: AbbVie Wins First Round in Humira Antitrust Lawsuit -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from November 2020.
-
Read more: Challenges in COVID-19 Vaccine Rollout: Lessons from the UK Challenges in COVID-19 Vaccine Rollout: Lessons from the UK
The U.S. can and should cautiously assess the U.K.’s vaccination strategy to avoid challenges that may impede its ability to control the virus.
-
Read more: Preparing for Antimicrobial Resistance: Vision and Social Science Mission of the INAMRSS Network Preparing for Antimicrobial Resistance: Vision and Social Science Mission of the INAMRSS Network
While drug-resistant infections pose a well-known and severe threat to human and animal health, the COVID-19 pandemic is compounding this situation.
-
Read more: Benefits and Drawbacks of Emergency Use Authorizations for COVID Vaccines Benefits and Drawbacks of Emergency Use Authorizations for COVID Vaccines
The EUA pathway may impede vital scientific progress needed to establish the long term safety and efficacy of investigational COVID-19 vaccines.
-
Read more: COVID-19 and the FDA Emergency Use Authorization Power COVID-19 and the FDA Emergency Use Authorization Power
This blog post provides an overview of the FDA’s emergency authorization powers and analyzes the extent of their usage in the COVID-19 pandemic.
-
Read more: Issuing the Most Favored Nation Interim Final Rule Was a Mistake Issuing the Most Favored Nation Interim Final Rule Was a Mistake
Procedurally, the Trump administration’s issuance of the Most Favored Nation Interim Final Rule was a mistake.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2020.
-
Read more: Cuts to 340B Drug Reimbursement May be Harmful During COVID-19 Cuts to 340B Drug Reimbursement May be Harmful During COVID-19
Slashing Medicare reimbursement for safety-net hospitals may have devastating effects on the individuals who rely on these hospitals.
-
Read more: Antibiotics in Agriculture: Preventing the Next Pandemic Antibiotics in Agriculture: Preventing the Next Pandemic
Event Description To help kick off Antibiotic Awareness Week, please join us for this panel event that will explore how research, collaboration, and policy can encourage better antibiotic stewardship in animal agriculture and human health care. COVID-19 may not be the only pandemic of our lifetime. For decades, scientists have warned that bacteria are getting…
